Role of Growth Factors & Neurophysiological Markers In Evaluation of Neuroplasticity Using 1Hz rTMS With Physical Therapy In Ischemic Stroke: A Double Blind, Parallel Group, Sham Controlled Randomized Trial
Abstract Background: The therapeutic benefits of repetitive trans cranial magnetic stimulation along with physical therapy to study the neuroplasticity and neurogenesis in ischemic stroke patients has not been fully elucidated. The aim of this study is to determine the neuroplasticity using serum growth factors as a surrogate marker, using 1Hz rTMS with conventional physiotherapy in patients with sub acute ischemic stroke.Methods: In this study, participants with first ever ischemic stroke (N = 96), onset within 15 days were randomized after a run-in period of 75 ± 7 days along with standard physical therapy to receive 10 sessions of real 1Hz rTMS (N = 47) on contralesional premotor cortex or to sham stimulation (N = 49) for 2 weeks. Participants, investigators and outcome assessors were blinded. The primary efficacy outcome was change in the level of peripheral serum growth factors VEGF & BDNF at third month. The secondary outcome was measurement of neurophysiological parameters and their correlation with growth factors levels.Results: Modified intention to treat analysis showed significant up regulation in the mean level of serum VEGF & BDNF from pre to post rTMS in Real rTMS Group. Trend of decrease in Resting Motor Threshold and increase in Motor Evoked Potential in the affected hand was seen. Statistically significant negative correlation between motor evoked potential and mean VEGF (rho = -1.000, P<0.001) in the affected hand in Real rTMS Group was seen.Conclusion: Total ten sessions of 1Hz rTMS plus physical therapy on contralateral hemisphere resulted in up regulation of serum growth factors possible reflecting improved neuroplasticity. Trial funded by Indian Council of Medical Research (ICMR), India, CTRI/2016/02/006620. Retrospectively registered. Note: As this is not a regulatory trial, therefore under Indian regulatory authorities, ICMR, any trial registered before 1st April 2018 was registered as retrospective study. Ethics committee approval for this study was taken in 2012.